| Abstrakt: |
A study conducted at Shenzhen Children's Hospital in China evaluated the effectiveness and safety of canakinumab in Chinese patients with Cryopyrin-Associated Periodic Syndrome (CAPS). CAPS is characterized by excessive IL-1b release, leading to systemic and organ inflammation. Canakinumab, an anti-IL-1 agent, has been approved for CAPS treatment in the USA and European countries, but its use in Chinese patients has been rarely reported. The study found that canakinumab was effective and well-tolerated in Chinese CAPS patients, reducing the need for corticosteroids. However, further trials with larger sample sizes are needed to evaluate its efficacy and safety in China. [Extracted from the article] |
